IP Library Granted Patent US 7,662,965
Granted Patent B2
US 7,662,965 · App. 11/698,267 · Granted Feb 16, 2010

Anabaseine derivatives, pharmaceutical compositions and method of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,662,965
App. No.
11/698,267
Granted
Feb 16, 2010
Kind
B2
Abstract

Disclosed are novel anabaseine derivatives that act as agonists of the α7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

Claims (19)

1. A compound of the following formula:

or a pharmaceutically acceptable salt thereof, wherein:

Each D is independently selected from the group consisting of C1-C10 alkyl, C1-C10 alkyl substituted with one or more R 8 , C2-C10 alkenyl, C2-C10 alkenyl substituted with one or more R 8 , C2-C10 alkynyl, C2-C10 alkynyl substituted with one or more R 8 , C3-C10 cycloalkyl, C3-C10 cycloalkyl substituted with one or more R 9 , C4-C10 cycloalkenyl, C4-C10 cycloalkenyl substituted with one or more R 9 , 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkyl substituted with one or more R 9 , 4-10 membered heterocycloalkenyl, 4-10 membered heterocycloalkenyl substituted with one or more R 9 , C5-C11 bicycloalkyl, C5-C11 bicycloalkyl substituted with one or more R 9 , C5-C11 bicycloalkenyl, C5-C11 bicycloalkenyl substituted with one or more R 9 , 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkyl substituted with one or more R 9 , 5-11 membered heterobicycloalkenyl, 5-11 membered heterobicycloalkenyl substituted with one or more R 9 , halo, haloalkyl, OR 7 , SR 7 , NR 7 R 7 , C(O)OR 7 , NO 2 , CN, C(O)R 7 , C(O)C(O)R 7 , C(O)NR 7 R 7 , C(O)C(O)NR 7 R 7 , N(R 7 )C(O)R 7 , NR 7 S(O) q R 7 , N(R 7 )C(O)OR 7 , NR 7 C(O)C(O)R 7 , NR 7 C(O)NR 7 R 7 , NR 7 S(O) q NR 7 R 7 , NR 7 S(O) q R 7 , S(O) q R 7 , S(O) q NR 7 R 7 , OC(O)R 7 , aryl and heteroaryl, wherein said aryl and heteroaryl are each optionally substituted with one or more R 11 ;

Each R 7 is independently selected from the group consisting of H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, 3-10 membered heterocycloalkyl, 4-10 membered heterocycloalkenyl, haloalkyl, aryl and heteroaryl, wherein said aryl and heteroaryl are each optionally substituted with one or more R 11 ;

Each R 8 is independently selected from the group consisting of halo, haloalkyl, OR 7 , SR 7 , C(O)R 7 , OC(O)R 7 , C(O)OR 7 , NR 7 R 7 , NO 2 , CN, OC(O)NR 7 R 7 , C(O)NR 7 R 7 , N(R 7 )C(O)R 7 , N(R 7 )(COOR 7 ), S(O) q NR 7 R 7 , C3-C8 cycloalkyl, C4-C10 cycloalkenyl, 3-8 membered heterocycloalkyl, 4-10 membered heterocycloalkenyl, C5-C11 bicycloalkyl, C5-C11 bicycloalkenyl, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, aryl and heteroaryl, wherein said aryl and heteroaryl are each optionally substituted with one or more R 11 ;

Each R 9 is independently selected from the group consisting of R 8 , C1-C10 alkyl, C1-C10 alkyl substituted with one or more R 8 , C2-C10 alkenyl, C2-C10 alkenyl substituted with one or more R 8 , C2-C10 alkynyl and C2-C10 alkynyl substituted with one or more R 8 ;

R 10 is aryl or heteroaryl, wherein said aryl and heteroaryl are each optionally substituted with one or more R 11 ;

Each R 11 is independently selected from the group consisting of C1-C10 alkyl, C1-C10 alkyl substituted with one or more R 8 , C2-C10 alkenyl, C2-C10 alkenyl substituted with one or more R 8 , C2-C10 alkynyl, C2-C10 alkynyl substituted with one or more R 8 , C3-C10 cycloalkyl, C3-C10 cycloalkyl substituted with one or more R 9 , C4-C10 cycloalkenyl, C4-C10 cycloalkenyl substituted with one or more R 9 , 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkyl substituted with one or more R 9 , 4-10 membered heterocycloalkenyl, 4-10 membered heterocycloalkenyl substituted with one or more R 9 , C5-C11 bicycloalkyl, C5-C11 bicycloalkyl substituted with one or more R 9 , C5-C11 bicycloalkenyl, C5-C11 bicycloalkenyl substituted with one or more R 9 , 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkyl substituted with one or more R 9 , 5-11 membered heterobicycloalkenyl, 5-11 membered heterobicycloalkenyl substituted with one or more R 9 , halo, haloalkyl, OR 7 , SR 7 , NR 7 R 7 , C(O)OR 7 , NO 2 , CN, C(O)R 7 , C(O)C(O)R 7 , C(O)NR 7 R 7 , N(R 7 )C(O)R 7 , NR 7 S(O) 2 R 7 , N(R 7 )C(O)OR 7 , NR 7 C(O)C(O)R 7 , NR 7 C(O)NR 7 R 7 , NR 7 S(O) q NR 7 R 7 , NR 7 S(O) q R 7 , S(O) q R 7 , S(O) q NR 7 R 7 , OC(O)R 7 , optionally substituted aryl and optionally substituted heteroaryl;

k is an integer from 0 to 4;

Each q is independently 1 or 2.

2. The compound of claim 1 wherein k is 0 or 1.

3. The compound of claim 1 wherein R 10 is selected from the group consisting of 6 membered monocyclic aryl, 5 or 6 membered monocyclic heteroaryl comprising 1-3 heteroatoms, 8-12 membered bicyclic aryl, 8-12 membered bicyclic heteroaryl comprising 1-6 heteroatoms, 11-14 membered tricyclic aryl and 11-14 membered heteroaryl comprising 1-9 heteroatoms, wherein each of said heteroatoms is independently selected from the group consisting of O, N and S and wherein each of said aryl and heteroaryl is optionally substituted with one or more R 11 .

4. The compound of claim 3 wherein R 10 is selected from the group consisting of 6 membered monocyclic aryl and 5 or 6 membered monocyclic heteroaryl comprising 1-3 heteroatoms, wherein each of said heteroatoms is independently selected from O, S and N, and wherein each of said aryl and heteroaryl is optionally substituted with one or more R 11 .

5. The compound of claim 4 wherein the compound is methyl 3-(5-((5,6-dihydro-2-(pyridin-3(4H)-ylidene)methylfuran-2-yl)thiophene-2-carboxylate.

6. The compound of claim 4 wherein R 10 is:

7. The compound of claim 6 wherein there is an R 11 substitution at the 2-position of the phenyl ring.

8. The compound of claim 7 wherein the compound is selected from the group consisting of 3-(3-(2,5-dichlorophenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3,4,5,6-tetrahydro-3-((5-(2-trifluoromethoxy)phenyl)furan-2-yl)methylene)pyridin-2-yl)pyridine, 3-3-((5-(2-chloro-5-(trifluoromethyl)phenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-((5-2-chloro-4-(trifluoromethyl)phenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-((5-(2,4-dichlorophenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-((5-(4-chloro-2-nitrophenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-((5-(2-fluorophenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-((5-o-tolylfuran-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-((5-(2-chlorophenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-((5-(2-trifluoromethyl)phenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-((5-(2,4-dimethoxyphenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine and 3-(3-((5-(2-fluoro-3-(trifluoromethyl)phenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine.

9. The compound of claim 6 wherein the compound is selected from the group consisting of 3-(3-((5-phenylfuran-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-((5-(4-chlorophenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-((5-(3-chlorophenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-((5-(3,4-dichlorophenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-((5-(3-chloro-4-methoxyphenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-((5-(3,5-bis(trifluoromethyl)phenyl)furan-2-yl)methylene-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-((5-(5-(4-fluoro-3-(trifluormethyl)phenyl)furan-2-yl)methylene-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3,4,5,6-tetrahydro-3-((5-(2-nitrophenyl)furan-2-yl)methylene)pyridin-2-yl)pyridine, 3-(3,4,5,6-tetrahydro-3-((5-(3-nitrophenyl)furan-2-yl)methylene)pyridin-2-yl)pyridine, 3-(3-((5-(4-chloro-2-nitrophenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-(5-(4-fluorophenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine, 3-(3-((5-(2-chloro-5-(trifluoromethyl)phenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyrdin-2-yl)pyridine, 3-(3,4,5,6-tetrahydro-3-((5,6-(trifluoromethoxy)phenyl)furan-2-yl)methylene)pyridin-2-yl)pyridine and 3-(3-((5-(3-(trifluoromethyl)phenyl)furan-2-yl)methylene-3,4,5,6-tetrahydropyridin-2-yl)pyridine

10. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and an effective amount of a compound of claim 1 .

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2014
From: CHIESI USA, INC.
To: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 034283/0331 →
CHANGE OF NAME Recorded Nov 26, 2014
From: CORNERSTONE THERAPEUTICS INC.
To: CHIESI USA, INC.
Reel/Frame 034455/0796 →
CHANGE OF NAME Recorded Jan 5, 2009
From: CRITICAL THERAPEUTICS, INC.
To: CORNERSTONE THERAPEUTICS, INC.
Reel/Frame 022052/0747 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2007
From: HABGOOD, GREGORY J.; ELBAUM, DANIEL
To: CRITICAL THERAPEUTICS, INC.
Reel/Frame 019425/0112 →